Department of Public Health and Clinical Medicine, Umeå University, 905 81, Umeå, Sweden.
Int Urogynecol J. 2022 May;33(5):1273-1282. doi: 10.1007/s00192-022-05137-1. Epub 2022 Mar 12.
A previous randomized controlled trial (RCT) demonstrated that the app Tät II, for self-management of mixed urinary incontinence (MUI) and urgency urinary incontinence (UUI), yielded significant, clinically relevant improvements in symptom severity and quality of life (QoL) compared with a control group. We aimed to assess the cost-effectiveness of Tät II.
A cost-utility analysis with a 1-year societal perspective was carried out, comparing Tät II with an information app. Data were collected alongside an RCT: 122 community-dwelling women aged ≥18 years with MUI or UUI ≥2 times/week were randomized to 3 months of Tät II treatment focused on pelvic floor muscle training (PFMT) and bladder training (BT; n = 60), or to an information app (n = 62). Self-assessed data from validated questionnaires were collected at baseline and at 3-month and 1-year follow-ups. Costs for assessment, treatment delivery, incontinence aids, laundry, and time for PFMT and BT were included. We calculated quality-adjusted life-years (QALYs) using the International Consultation on Incontinence Modular Questionnaire Lower Urinary Tract Symptoms Quality of Life. The incremental cost-effectiveness ratio (ICER) between the groups was our primary outcome. Sensitivity analyses were performed.
The mean age was 58.3 (SD = 9.6) years. Annual overall costs were €738.42 in the treatment group and €605.82 in the control group; annual QALY gains were 0.0152 and 0.0037 respectively. The base case ICER was €11,770.52; ICERs in the sensitivity analyses ranged from €-9,303.78 to €22,307.67.
The app Tät II is a cost-effective treatment method for women with MUI and UUI.
先前的一项随机对照试验（RCT）表明，用于混合性尿失禁（MUI）和急迫性尿失禁（UUI）自我管理的应用程序 Tät II 与对照组相比，在症状严重程度和生活质量（QoL）方面产生了显著的、具有临床意义的改善。我们旨在评估 Tät II 的成本效益。
进行了一项具有 1 年社会视角的成本效用分析，比较了 Tät II 与信息应用程序。数据是在 RCT 中收集的：122 名年龄在 18 岁及以上、每周至少出现 2 次 MUI 或 UUI 的社区居民被随机分为 3 个月的 Tät II 治疗组，重点是盆底肌肉训练（PFMT）和膀胱训练（BT）（n = 60），或信息应用程序组（n = 62）。基线和 3 个月和 1 年随访时，使用经过验证的问卷收集自我评估数据。包括评估、治疗提供、失禁辅助设备、洗衣和 PFMT 和 BT 时间的费用。我们使用国际尿失禁咨询下尿路症状生活质量模块问卷计算了质量调整生命年（QALY）。两组之间的增量成本效益比（ICER）是我们的主要结果。进行了敏感性分析。
平均年龄为 58.3（SD = 9.6）岁。治疗组的年总费用为 738.42 欧元，对照组为 605.82 欧元；年 QALY 收益分别为 0.0152 和 0.0037。基础病例的 ICER 为 11770.52 欧元；敏感性分析中的 ICER 范围为-9303.78 至 22307.67 欧元。
应用程序 Tät II 是治疗 MUI 和 UUI 女性的一种具有成本效益的治疗方法。
